Acrux Limited (ARUXF)

0.0477 0.0000 (0.00%) At close: 10:30AM EDT

Acrux Limited

103-113, Stanley Street
West Melbourne, VIC 3003
Australia
61 3 8379 0100
https://www.acrux.com.au

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus	CEO, MD & Exec. Director	342.8k	N/A	1966
Ms. Joanna Johnson B.E., BEc, ICAA	CFO & Company Sec.	188.18k	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.

Corporate Governance

Acrux Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.